You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The development of Sanaria's aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoite (SPZ)-based products has received international recognition during the past year, due principally to four findings: 1)PfSPZ Challenge (infectious PfSPZ) induced malaria in volunteers, 2) PfSPZ Vaccine (radiation attenuated PfSPZ) induced unprecedented levels ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Development of RLIP76 protein as a Radiation Countermeasure

    SBC: TERAPIO            Topic: NIAID

    DESCRIPTION (provided by applicant): There remains a critical need for medicines that can counteract the toxic effects of radiation exposure. Terapio is developing a recombinant protein, RLIP76, for use as a radioprotectant for workers, military personnel, or civilians that are either in imminent danger of radiation exposure, or have already been exposed. In research carried out at the Unive ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Transgenic Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): An ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmission. Sanaria's goal is to develop and commercialize a Pf sporozoite (SPZ) vaccine that prevents Pf blood stage infection in gt 90% ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluation and Production of a Multivalent Adenoviral Plague Vaccine

    SBC: NORWELL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The final objective of this Phase II SBIR is to complete preclinical studies of a trivalent adenoviral vaccine against plague in preparation for human clinical trials. The plague vaccine project was selected in responseto the growing concern surrounding the organism's possible use in a terrorism event. The NIAID and CDC, in response to this threat, has cla ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. N-Methanocarbathymidine (N-MCT) for the treatment of herpes and pox virus infecti

    SBC: N&N Pharmaceuticals, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Diseases associated with the Poxviridae (smallpox, vaccinia and cowpox viruses), and Herpesviridae (HSV-1, HSV-2, HSV-8, VZV, EBV) dsDNA viruses represent major worldwide public health problems. NandN Scientific, Inc. (NandN) is developing a first of its class broad-spectrum orally bioavailable antiviral drug, N- methanocarbathymidine (N-MCT), which has exhibit ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure

    SBC: Chrysalis BioTherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): With recent radiation release from reactors in Japan and increasing probability of nuclear detonation somewhere in the world, there is a critical need for development of effective medicinal counter-measures that can bedelivered after exposure to prevent radiation-induced mortality. Adding to this need, mortality increases significantly when radiation is combine ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Neural Plasticity for the Treatment of Tinnitus

    SBC: MICROTRANSPONDER, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): This is a proposal to conduct a multi-center, double-blind, sham-controlled partial cross-over interventional study to test safety and efficacy of our novel tinnitus therapy. The tinnitus field generally accepts that elevated synchronous spontaneous activity in the auditory cortex may account for the tinnitus percept that arises following hearing loss. Followin ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. IGF::OT::IGF OTHER FUNCTIONS DEVELOPMENT OF TOOLS FOR CRYOGENIC BIOPSY OF SOFT TISSUE.

    SBC: ROBIN MEDICAL INC            Topic: NCI

    Molecular medicine holds promise for advancing cancer diagnosis and treatment if biomarkers can be accurately assessed in tumors. The objective of the project is to develop and test a new biopsy system that stabilizes the target tissue and prevents changes in biomarker levels due to ischemia in the excised tissue sample. The specific aims of the project are: 1. Design and build a clinic-ready, ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Sutureless Laparoscopic Partial Nephrectomy Using Laser Tissue Welding: Preclinic

    SBC: Laser Tissue Welding, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): Preservation of functioning renal parenchyma is important and nephron-sparing surgery substitutes for radical nephrectomy in appropriately selected patients with renal cell carcinoma. Laparoscopic partial nephrectomy (LPN) has demonstrated excellent outcomes in terms of oncologic control, but is under-used due to major technical challenges of parenchymal hemost ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Prospective/Retrospective Motion Correction System for Motion Robust Pediatric MR

    SBC: ROBIN MEDICAL INC            Topic: NIMH

    DESCRIPTION (provided by applicant): The long term objective of the project is to develop a new motion robust magnetic resonance imaging (MRI) technology. Magnetic resonance imaging is a powerful tool that aids in the diagnosis of individual subjects, guides their clinical care, ad provides insights into the mechanisms of normal and atypical development. The characterization of mental health disor ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government